Clinical trial · Observational
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction Magnetic Resonance Imaging (MRI)
NCT06201351CI-TRIAL-00072920not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by MRI image between radiotherapy fractions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High-grade Glioma | High-Grade Glioma, NOS | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| adaptive radiotherapy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Adaptive radiotherapy group
- description
- MRI was performed and adaptive radiotherapy was administered at farction10 and fraction 20 during radiotherapy.
- interventionNames
- Device: adaptive radiotherapy
Primary outcomes (3)
- measure
- Homogeneity index
- timeFrame
- up to 2 weeks
- description
- HI: Homogeneity index. Dosimetric change
- measure
- conformity index
- timeFrame
- up to 2 weeks
- description
- CI: conformity index. Dosimetric change
- measure
- Anatomic change
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years old; 2. High-grade glioma was confirmed by pathology after surgery; 3. ECOG score 0-2 points; 4. Receiving the standard STUPP regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy); 5. Baseline data available. Exclusion Criteria: 1. The pathological diagnosis is not clear; 2. No synchronous chemotherapy/adjuvant chemotherapy \< 6 cycles; 3. There are other malignant tumors; 4. Previously radiotherapy to the head; 5. Interruption of radiotherapy for more than 5 days; 6. Failure to collect baseline data.
References
Publications (1)
- DERIVEDHe S, Yu H, Yang Y, Mao Q, Wang X, Zeng Y, Wang F, Liu M, Li Y, Gao K, Peng X, Liu Y, Ai P. Study of Adaptive Radiotherapy for High-Grade Glioma Based on Interfraction MRI. Cancer Med. 2026 Sep;15(9):e72225. doi: 10.1002/cam4.72225. PMID 42675793